In this study, we found no evidence of malignant transformation in our patients, which conflicts with other published data conferring an 11%-14% risk of malignant transformation. An international consensus opinion needs to be reached within the Gestational trophoblastic community regarding the optimal advice, management, and follow-up regimens for patients diagnosed with APSN.
Parker et al. (2026) studied this question.